Tempest Therapeutics, Inc. (TPST) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-17.49 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.50 vs est $-17.49 (beat +91.4%). 2025: actual $-6.33 vs est $-6.10 (missed -3.8%). Analyst accuracy: 0%.
TPST Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Tempest Therapeutics, Inc. in the past 3 months
EPS Estimates — TPST
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.50
vs Est –$17.49
▲ 1,066.3% off
2025
Actual –$6.33
vs Est –$6.10
▼ 3.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — TPST
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
